Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Increased Clostridium Difficile Infections Due to Antibiotic Misuse

By LabMedica International staff writers
Posted on 11 Mar 2015
Changes in the epidemiology of Clostridium difficile infections have occurred since the emergence of the North American pulsed-field gel electrophoresis type 1 (NAP1) strain, which has been responsible for geographically dispersed hospital-associated outbreaks.

Clostridium difficile is a bacterium that causes colitis and inflammation of the colon and infection can occur through touching surfaces or items that are contaminated with feces, in which the bacteria are is shed. More...
People who are taking antibiotics for other illnesses are most prone to C. difficile infection as antibiotics can destroy some of the friendly bacteria in the gut, meaning it may be less protected against C. difficile.

A team of investigators led by those at the Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) identified all positive C. difficile test results from 88 inpatient and 33 outpatient laboratories serving residents in surveillance areas in 2011. A case of C. difficile infection was defined as a positive result on a C. difficile toxin or molecular assay of a stool specimen obtained from a surveillance-area resident at least one year of age who had not had a positive assay in the previous eight weeks. Recovered isolates underwent pulsed-field gel electrophoresis (PFGE) and also underwent polymerase-chain-reaction (PCR) assay to detect the presence of particular genes.

A total of 15,461 cases of C. difficile infection were identified in the 10 geographic areas; 65.8% were healthcare associated, but only 24.2% had onset during hospitalization. The North American pulsed-field gel electrophoresis type 1 (NAP1) strain was more prevalent among healthcare-associated infections than among community-associated infections. The study found that individuals aged 65 and older are particularly vulnerable to C. difficile infection. Around one in three cases occurred among patients in this age group, and they also accounted for two in three healthcare-associated C. difficile infections. What is more, around 80% of C. difficile-attributable deaths occurred in patients aged 65 or older.
The team also identified an increased risk of C. difficile infection among women and Caucasian individuals.

The CDC say these results indicate that improved antibiotic use and infection control needs to be put in place for outpatient health care, as well as inpatient facilities. Michael Bell, MD, deputy director of the Division of Healthcare Quality and Promotion at the CDC, said, “Overall, there are two main things that need to be improved. Number one is how antibiotics are being used, making sure that we use them when they're truly necessary and only for as long as necessary. The second element is to ensure rigorous infection control in all health care settings. C. difficile infections must be diagnosed quickly and correctly so that the infected patient can be cared for using the right infection control techniques.” The study was published on February 26, 2015, in the New England Journal of Medicine.

Related Links:

The Centers for Disease Control and Prevention 



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.